Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
Clinical Trial Results Expected First Half 2019 SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: […]